Archive ready
新型コロナウイルス治療薬の特例承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_27695.htmlApril 9, 2026 at 09:01 PM JST•The archive page, viewer, and downloads use this saved version.
April 9, 2026 at 09:01 PM JST·www.mhlw.go.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved page
新型コロナウイルス治療薬の特例承認について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
Original URLhttps://www.mhlw.go.jp/stf/newpage_27695.html
StartedApril 9, 2026 at 09:01 PM JST
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
About this pageAI generated
This page announces the special approval of a COVID-19 therapeutic drug by Japan's Ministry of Health, Labour and Welfare on August 30, 2022. Under the Pharmaceutical Affairs Law, "Evusheld Intramuscular Injection Set" (tixagevimab and cilgavimab) submitted by AstraZeneca was approved. The drug is used for treating SARS-CoV-2 infection and preventing its onset. The application was filed on June 9, 2022, with attached documents available separately.
